Inari Medical, Inc. (NASDAQ:NARI) Given Average Rating of “Hold” by Brokerages

Inari Medical, Inc. (NASDAQ:NARI) has been given an average rating of “Hold” by the fourteen brokerages that are presently covering the firm, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $68.00.

Several equities research analysts have issued reports on NARI shares. Canaccord Genuity Group reissued a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 price objective (up from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. BTIG Research reaffirmed a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. William Blair reissued a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective (down from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th.

Insiders Place Their Bets

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. This trade represents a 0.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now owns 238,987 shares in the company, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 323,000 shares of company stock worth $18,669,070 over the last 90 days. Corporate insiders own 10.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of Inari Medical by 128.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock worth $33,000 after purchasing an additional 356 shares during the last quarter. R Squared Ltd acquired a new stake in Inari Medical in the fourth quarter valued at $45,000. GAMMA Investing LLC lifted its holdings in Inari Medical by 67.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after buying an additional 473 shares during the last quarter. KBC Group NV boosted its position in shares of Inari Medical by 39.0% during the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Inari Medical in the 2nd quarter valued at about $104,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $79.76 on Friday. The company has a market capitalization of $4.67 billion, a P/E ratio of -59.08 and a beta of 1.02. The company has a 50 day simple moving average of $65.69 and a 200-day simple moving average of $53.26. Inari Medical has a 1 year low of $36.73 and a 1 year high of $79.93.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.